| |
|
|
| |
|
|
| |
HUM-MOLGEN
-> Events
-> Courses and Workshops |
|
|
| |
| |
| |
September 30, 2015 |
|
|
| |
|
|
| |
|
|
|
CfPA-The Center for Professional Advancement, 90 Minute Accredited Online Training
November 19, 2015 at 11:00 a.m.–12:30 p.m. (ET)
Who Should Attend?
This course is intended for professionals in roles such as Supervisors and manager and for related personnel involved in production of products in compounding pharmacies. Course Description
|
|
|
|
|
|
|
|
Organized by:
|
|
CfPA-The Center for Professional Advancement |
|
|
Invited Speakers:
|
|
| William G. Marshall; President, William G. Marshall & Associates |
William G. Marshall is President of William G. Marshall and Associates. He has nearly forty years experience in the Pharmaceutical and Medical Device Manufacturing Environment. Mr. Marshall has held Director level and Chief Operating Officer positions with large multinational pharmaceutical corporations as well as start-up ventures. He has been the Director of a major reference laboratory, and has been active in clean room design and validation. In the last five years, he has acted as a third party in several consent decrees.
Mr. Marshall is currently a consultant to the worldwide drug and device industry as well as to the FDA. He lectures worldwide in GMP related issues including Clean Room Technology and Sterilization.
Marshall has 40 plus years of experience in cGMPs and recently has been involved with several compounders and their FDA interface.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
n/a
|
|
|
|
|
|
|
|
Registration:
|
|
Please click here for registration information.
|
|
|
E-mail:
|
|
sberg@cfpa.com
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp,
Frank S.
Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved.
Liability, Copyright and Imprint. |
|
This 90-minute, accredited training will look at the areas that FDA is focusing on with these 483s and the over eighty warning letters that have been issued.
It will discuss trends as seen in these 483. It will also cover how to respond to a 483 and suggest corrective actions. It will also look at areas of the Pharmaceutical cGMPs where the FDA has not yet been targeting but might in the future.
Can't Make this LIVE Webinar?
Simply select the On Demand option when registering and we will send you the link to view the recorded version.
This course will be available On Demand: November 20, 2015